In a bold move to secure a position in the high-stakes obesity drug market, global pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced its agreement to acquire biotechnology company Metsera for a total potential consideration of up to $7.3 billion.
The acquisition structure includes an upfront payment of approximately $4.9 billion, with an additional $2.4 billion available through contingent value rights (CVRs) tied to the successful development and regulatory approval of Metsera’s key drug candidates.
Under the terms, Pfizer will pay $47.50 per share for Metsera, representing a 43% premium to its previous closing price. The CVR agreement could provide Metsera shareholders with up to $22.50 per share extra upon achieving specific milestones:
This milestone-based structure underscores Pfizer’s confidence in the pipeline while mitigating some risk. The market reaction was immediate, with Metsera’s stock surging over 60% on the announcement. However, the current share price remains below the total potential value including all CVR payments, reflecting investor caution regarding the candidates’ regulatory hurdles.
The core appeal for Pfizer lies in Metsera’s innovative obesity treatment portfolio, which aims to challenge the current weekly injection regimens of blockbuster drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
The lead assets include:
Metsera’s technology platform enables its drugs to bind to albumin, a abundant blood protein, allowing therapeutic levels to be maintained longer with relatively low doses, potentially improving patient tolerability.
The acquisition is a strategic imperative for Pfizer as it faces a significant “patent cliff,” with exclusivity expiring for top-selling drugs like the anticoagulant Eliquis. This is projected to erode $17-$18 billion in annual revenue over the next few years.
Entering the massive obesity market is key to offsetting these losses. Goldman Sachs has conservatively projected the global GLP-1 drug market to reach $95 billion in annual sales by 2030. Pfizer’s CEO, Albert Bourla, has previously told investors that acquired products could generate $20 billion in annual revenue by 2030. The Metsera buyout is a pivotal step toward that goal, potentially setting the stage for a three-way competition in the lucrative obesity drug market.
